Death (all causes) · people with diabetes and kidney disease
Angiotensin‐converting‐enzyme inhibitors (ACEi) alone showed no clear difference in all‐cause death Median compared with ACEi plus angiotensin receptor blockers (low certainty).
1 finding from 1 review
Cardiovascular mortality · people with diabetes and kidney disease
Angiotensin‐converting‐enzyme inhibitors (ACEi) alone showed no clear difference in cardiovascular death Median compared with ACEi plus angiotensin receptor blockers (low certainty).
1 finding from 1 review
Doubling of SCr Median · people with diabetes and kidney disease
Angiotensin‐converting‐enzyme inhibitors (ACEi) alone showed no clear difference in doubling of SCr Median compared with ACEi plus angiotensin receptor blockers (low certainty).
1 finding from 1 review
Fatal or nonfatal stroke · people with diabetes and kidney disease
Angiotensin‐converting‐enzyme inhibitors (ACEi) alone showed no clear difference in fatal or nonfatal stroke Median compared with ACEi plus angiotensin receptor blockers (low certainty).
1 finding from 1 review
Fatal or nonfatal myocardial infarction · people with diabetes and kidney disease
Angiotensin‐converting‐enzyme inhibitors (ACEi) alone showed no clear difference in fatal or nonfatal myocardial infarction Median compared with ACEi plus angiotensin receptor blockers (low certainty).
1 finding from 1 review
Micro‐ to macroalbuminuria Median · people with diabetes and kidney disease
It is very uncertain whether angiotensin‐converting‐enzyme inhibitors (ACEi) alone changes micro‐ to macroalbuminuria Median compared with ACEi plus angiotensin receptor blockers (very low certainty).
1 finding from 1 review
Micro‐ to normoalbuminuria Median · people with diabetes and kidney disease
Angiotensin‐converting‐enzyme inhibitors (ACEi) alone showed no clear difference in micro‐ to normoalbuminuria Median compared with ACEi plus angiotensin receptor blockers (low certainty).
1 finding from 1 review
Improvement in WHO functional class · people with pulmonary hypertension due to lung disease
Group 3 Pulmonary hypertension due to lung disease ‐ PDE5i may leads to higher improvement in WHO functional class compared with placebo (low certainty).
1 finding from 1 review
Six‐minute walk distance · people with pulmonary hypertension due to lung disease
1 finding from 1 review
All‐cause mortality · people with pulmonary hypertension due to lung disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Quality of life · people with pulmonary hypertension due to lung disease
1 finding from 1 review
PAP · people with pulmonary hypertension due to lung disease
1 finding from 1 review
Cardiac index · people with pulmonary hypertension due to lung disease
1 finding from 1 review
PVR · people with pulmonary hypertension due to lung disease
1 finding from 1 review
RAP · people with pulmonary hypertension due to lung disease
1 finding from 1 review
Quantity and quality of sleep as measured through reports of participants or family members or by personnel assessments Data collected at end of study · critically ill adult patients
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Quantity and quality of sleep as measured by PSG, actigraphy, BIS or EEG Data collected at end of study · critically ill adult patients
1 finding from 1 review
Anxiety and depression · critically ill adult patients
1 finding from 1 review
Adverse events (such as cardiovascular events, respiratory events or illness resulting from immune deficiency) · critically ill adult patients
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Quantity and quality of sleep as measured by PSG, actigraphy, BIS or EEG Data collected at end of study · critically ill adult patients
1 finding from 1 review